Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 14 | 2024 | 2087 | 2.750 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2024 | 1405 | 1.720 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2024 | 757 | 1.500 |
Why?
|
| Anticholesteremic Agents | 2 | 2024 | 245 | 1.370 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 36 | 0.890 |
Why?
|
| Incretins | 1 | 2024 | 24 | 0.890 |
Why?
|
| Ageism | 1 | 2023 | 4 | 0.830 |
Why?
|
| Glucose Intolerance | 1 | 2024 | 83 | 0.820 |
Why?
|
| Obesity | 6 | 2025 | 2411 | 0.790 |
Why?
|
| Hypoglycemic Agents | 4 | 2024 | 480 | 0.780 |
Why?
|
| Vascular Stiffness | 1 | 2023 | 80 | 0.780 |
Why?
|
| Atherosclerosis | 3 | 2025 | 999 | 0.730 |
Why?
|
| Hypercholesterolemia | 1 | 2022 | 235 | 0.650 |
Why?
|
| Insulin Resistance | 2 | 2024 | 686 | 0.620 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 931 | 0.560 |
Why?
|
| Hypertension | 1 | 2023 | 1396 | 0.440 |
Why?
|
| Lipids | 2 | 2023 | 567 | 0.320 |
Why?
|
| Cholesterol, LDL | 2 | 2024 | 604 | 0.320 |
Why?
|
| Risk Factors | 7 | 2025 | 11085 | 0.290 |
Why?
|
| Humans | 23 | 2025 | 133414 | 0.280 |
Why?
|
| Nutrition Surveys | 2 | 2024 | 312 | 0.240 |
Why?
|
| Body Temperature Regulation | 1 | 2025 | 50 | 0.240 |
Why?
|
| Aspartic Acid | 1 | 2025 | 84 | 0.240 |
Why?
|
| Postprandial Period | 1 | 2025 | 91 | 0.230 |
Why?
|
| Adipokines | 1 | 2025 | 72 | 0.230 |
Why?
|
| Adiponectin | 1 | 2025 | 127 | 0.230 |
Why?
|
| Body Temperature | 1 | 2025 | 130 | 0.230 |
Why?
|
| Mitochondria, Muscle | 1 | 2024 | 38 | 0.220 |
Why?
|
| Adipocytes | 1 | 2025 | 166 | 0.220 |
Why?
|
| Anti-Obesity Agents | 1 | 2024 | 45 | 0.220 |
Why?
|
| Leptin | 1 | 2025 | 224 | 0.220 |
Why?
|
| Standard of Care | 1 | 2024 | 135 | 0.210 |
Why?
|
| Pulse Wave Analysis | 1 | 2023 | 51 | 0.210 |
Why?
|
| Proprotein Convertase 9 | 1 | 2024 | 82 | 0.210 |
Why?
|
| Exercise Tolerance | 1 | 2024 | 86 | 0.210 |
Why?
|
| Glucose Tolerance Test | 1 | 2024 | 224 | 0.200 |
Why?
|
| Weight Loss | 2 | 2024 | 511 | 0.200 |
Why?
|
| Cardiovascular System | 1 | 2024 | 111 | 0.200 |
Why?
|
| Patient Care | 1 | 2023 | 100 | 0.190 |
Why?
|
| Cause of Death | 1 | 2024 | 504 | 0.190 |
Why?
|
| Blood Glucose | 2 | 2024 | 1189 | 0.190 |
Why?
|
| Fatty Liver | 1 | 2024 | 215 | 0.190 |
Why?
|
| Obesity Management | 1 | 2021 | 2 | 0.190 |
Why?
|
| Metabolic Syndrome | 1 | 2025 | 365 | 0.180 |
Why?
|
| Sulfonylurea Compounds | 1 | 2021 | 19 | 0.180 |
Why?
|
| Prediabetic State | 1 | 2022 | 63 | 0.180 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2021 | 29 | 0.180 |
Why?
|
| Hypolipidemic Agents | 1 | 2023 | 187 | 0.180 |
Why?
|
| Thiazolidinediones | 1 | 2021 | 85 | 0.180 |
Why?
|
| Overweight | 1 | 2023 | 383 | 0.170 |
Why?
|
| Leg | 1 | 2021 | 156 | 0.170 |
Why?
|
| Ergocalciferols | 1 | 2019 | 5 | 0.160 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 142 | 0.160 |
Why?
|
| Aged | 8 | 2025 | 21609 | 0.160 |
Why?
|
| Insulin | 2 | 2021 | 1244 | 0.150 |
Why?
|
| Vitamins | 1 | 2019 | 111 | 0.150 |
Why?
|
| Albuminuria | 1 | 2019 | 115 | 0.150 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 536 | 0.150 |
Why?
|
| Life Style | 1 | 2021 | 453 | 0.150 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 76 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1193 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1154 | 0.130 |
Why?
|
| Comorbidity | 1 | 2021 | 1615 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 867 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2025 | 6570 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1334 | 0.110 |
Why?
|
| United States | 6 | 2024 | 11677 | 0.110 |
Why?
|
| Male | 9 | 2025 | 65692 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 793 | 0.100 |
Why?
|
| Female | 9 | 2025 | 71463 | 0.100 |
Why?
|
| Exercise | 3 | 2024 | 865 | 0.100 |
Why?
|
| Adult | 8 | 2024 | 31787 | 0.090 |
Why?
|
| Veterans | 1 | 2022 | 1765 | 0.080 |
Why?
|
| Middle Aged | 6 | 2025 | 29213 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 1033 | 0.060 |
Why?
|
| Prevalence | 2 | 2024 | 2651 | 0.060 |
Why?
|
| Adipose Tissue, White | 1 | 2025 | 89 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3733 | 0.060 |
Why?
|
| Glycolysis | 1 | 2024 | 170 | 0.050 |
Why?
|
| Health Status | 1 | 2025 | 412 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2024 | 306 | 0.050 |
Why?
|
| Mitochondrial Diseases | 1 | 2024 | 149 | 0.050 |
Why?
|
| Mortality | 1 | 2024 | 262 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2025 | 417 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 73 | 0.050 |
Why?
|
| Public Health | 1 | 2024 | 287 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 255 | 0.050 |
Why?
|
| Longevity | 1 | 2022 | 158 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2024 | 246 | 0.040 |
Why?
|
| Glucose | 1 | 2025 | 922 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2022 | 334 | 0.040 |
Why?
|
| Young Adult | 2 | 2024 | 9854 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2021 | 314 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 2210 | 0.040 |
Why?
|
| Heart | 1 | 2024 | 749 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2025 | 1709 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1241 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 240 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 264 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2019 | 150 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2025 | 3981 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2024 | 3642 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3688 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5455 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 4822 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 3424 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2021 | 867 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1734 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1654 | 0.030 |
Why?
|
| Adolescent | 2 | 2024 | 20505 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3696 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1483 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 7160 | 0.030 |
Why?
|
| Mice | 1 | 2025 | 18911 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17380 | 0.020 |
Why?
|
| Animals | 1 | 2025 | 36379 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12974 | 0.010 |
Why?
|